AAN 2024 Conference

Apr 24, 2024

Donanemab, with improved safety, efficacy, convenient dosing regime, and most importantly its ability to not only prevent but also clear plaques has the potential to redefine the treatment regime for Alzheimer’s patients. With a comparable safety profile, Eli Lilly delivers on even the most basic outcomes essen...

Apr 22, 2024

IPX203 represents a groundbreaking advancement in Parkinson's disease (PD) treatment with its novel oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules. Unlike existing options, IPX203 utilizes a unique combination of immediate-release granules and extended-release coated beads to provide both ...

Apr 22, 2024

Frexalimab (SAR441344) is a novel anti-CD40L antibody in development, designed to inhibit the CD40/CD40L pathway, a crucial element in activating both adaptive and innate immune responses. Its distinctive mode of action targets neuroinflammation in multiple sclerosis, offering potential benefits for both acute and...

Apr 22, 2024

AXS-07, a cutting-edge oral solution, blends MoSEIC meloxicam and rizatriptan, offering rapid absorption. It ingeniously inhibits CGRP release, counteracting vasodilation, and curbing neuroinflammation and pain transmission for enhanced relief. AXS-07 demonstrates superior efficacy in swiftly alleviating migrai...

Apr 22, 2024

UB-312 represents a promising avenue in Parkinson's disease (PD) treatment by focusing on pathological forms of alpha-synuclein (aSyn), a key protein associated with the progression of synucleinopathies. Unlike conventional approaches, UB-312 aims to elicit antibodies that specifically recognize and neutralize the...

Apr 22, 2024

ZEPOSIA (ozanimod), a breakthrough approved in March 2020 for Relapsing Forms of Multiple Sclerosis (RMS), utilizes oral sphingosine 1-phosphate (S1P) receptor modulation to impede lymphocyte migration, offering a novel approach in multiple sclerosis treatment. ENLIGHTEN (NCT04140305) explores ozanimod's impact...

Apr 22, 2024

NeuroDerm's ND0612 introduces a pioneering approach to Parkinson's disease management with its self-administered continuous subcutaneous infusion of levodopa/carbidopa. Unlike traditional oral formulations, ND0612 bypasses the gastrointestinal tract, offering increased bioavailability and potentially more reliable...

Apr 19, 2024

Eculizumab (SOLIRIS) and ravulizumab (ULTOMIRIS) are two approved therapies for the treatment for adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor antibody-positive. The findings presented by Alexion, AstraZeneca Rare Disease unveil a remarkable decline in Myasthenia G...

Apr 19, 2024

Efgartigimod (VYVGART/VYVGART Hytrulo) is a prescription medicine for the treatment of gMG in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive). It is designed as a first-in-class investigational antibody fragment to target the neonatal Fc ...

Apr 19, 2024

P2B001, a novel once-daily combination therapy, uniquely merges extended-release pramipexole and rasagiline in low doses, targeting Parkinson's Disease (PD) with enhanced efficacy and minimized side effects. The analysis presented by Pharma Two B highlighted P2B001's impressive safety and tolerability profile c...